Gastrointestinal Therapeutics in Asia-Pacific Market Size, Trend and Analysis Report 2019: Radiant Insights, Inc GBI Research, the leading business intelligence provider, has released its latest research, "Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need", which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications. Read Complete Report with TOC @ http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asiapacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-highregional-unmet-need Scope - Disease overview and treatment usage patterns - Market size and forecast for IBS, UC and CD in APAC market from 2012 to 2019 - Major marketed products for the indications types covered - In-depth pipeline analysis for IBS, UC and CD - Key drivers and restraints that have had and are expected to have a significant impact upon the market - Key licensing and co-development agreements in the gastrointestinal therapeutics market Reasons to buy - Align your product portfolio to the markets with high growth potential - Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market - Develop key strategic initiatives based upon an understanding of key focus areas and leading companies - Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships Table of Contents Table of Contents 6 1.1 List of Tables 9 1.2 List of Figures 10 2 Gastrointestinal Therapeutics in Asia-Pacific Market - Introduction 11 2.1 Irritable Bowel Syndrome 11 2.1.1 Classification 11 Read Complete Report with TOC @ http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asiapacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-highregional-unmet-need 2.1.2 Symptoms 11 2.1.3 Etiology 11 2.1.4 Pathophysiology 12 2.1.5 Diagnosis 12 2.1.6 Epidemiology 14 2.1.7 Prognosis 14 2.1.8 Treatment Options 14 2.2 Ulcerative Colitis 15 2.2.1 Classification 15 2.2.2 Symptoms 17 2.2.3 Etiology 17 2.2.4 Pathophysiology 17 2.2.5 Diagnosis 18 2.2.6 Epidemiology 19 2.2.7 Prognosis 19 2.2.8 Treatment Options 19 2.3 Crohn's Disease 21 2.3.1 Classification 21 2.3.2 Symptoms 22
2.3.3 Etiology 22 2.3.4 Pathophysiology 23 2.3.5 Diagnosis 23 2.3.6 Epidemiology 24 2.3.7 Prognosis 24 2.3.8 Treatment Options 25 3 Gastrointestinal Therapeutics in Asia-Pacific Market - Marketed Products (Global) 26 3.1 Irritable Bowel Syndrome 26 3.2 Ulcerative Colitis 26 3.3 Crohn's Disease 26 3.4 Key Marketed Products 27 3.4.1 Amitiza 27 3.4.2 Humira 28 Read Complete Report with TOC @ http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asiapacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-highregional-unmet-need 3.4.3 Remicade 29 3.4.4 Simponi 30 3.4.5 Cimzia 31 3.4.6 Tysabri 32 4 Gastrointestinal Therapeutics in Asia-Pacific Market - Pipeline Analysis 34 4.1 Irritable Bowel Syndrome 34 4.1.1 Overall Pipeline 34 4.1.2 Pipeline Analysis by Molecule Type 36 4.1.3 Pipeline Analysis by Mechanism of Action 37 4.2 Ulcerative Colitis Pipeline 39 4.2.1 Overall Pipeline 39 4.2.2 Pipeline Analysis by Molecule Type 41 4.2.3 Pipeline Analysis by Mechanism of Action 42 4.3 Crohn's Disease Pipeline 44 4.3.1 Overall Pipeline 44 4.3.2 Pipeline Analysis by Molecule Type 46 4.3.3 Pipeline Analysis by Mechanism of Action 47 4.4 Promising Drug Candidates in the Pipeline 49 4.4.1 GSK-1605786 49 4.4.2 MLN0002 49
4.4.3 EMD-61753 49 5 Gastrointestinal Therapeutics in Asia-Pacific Market - Market Forecast to 2019 50 5.1 Asia-Pacific Markets 50 5.1.1 Treatment Usage Patterns 50 5.1.2 Annual Cost of Therapy 50 5.1.3 Market Size 50 5.2 Australia 52 5.2.1 Treatment Usage Patterns 52 5.2.2 Annual Cost of Therapy 52 5.2.3 Market Size 52 5.3 India 54 Read Complete Report with TOC @ http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asiapacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-highregional-unmet-need 5.3.1 Treatment Usage Patterns 54 5.3.2 Annual Cost of Therapy 54 5.3.3 Market Size 54 5.4 China 56 5.4.1 Treatment Usage Patterns 56 5.4.2 Annual Cost of Therapy 56 5.4.3 Market Size 56 5.5 Japan 58 5.5.1 Treatment Usage Patterns 58 5.5.2 Annual Cost of Therapy 58 5.5.3 Market Size 58 5.6 Drivers and Barriers 60 5.6.1 Drivers 60 5.6.2 Barriers 60 6 Gastrointestinal Therapeutics in Asia-Pacific Market - Deals and Strategic Consolidations (Global) 61 6.1 Deals Analysis 61 6.2 Major Co-Development Deals 63 6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 64 6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 64
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 64 6.3 Major Licensing Deals 65 6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 66 6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 66 6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 66 7 Gastrointestinal Therapeutics in Asia-Pacific Market - Appendix 67 7.1 Market Definitions 67 7.2 Abbreviations 67 7.3 Sources 69 7.4 All Pipeline Drugs by Phase 71 7.4.1 Discovery 71 7.4.2 Preclinical 71 Read Complete Report with TOC @ http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asiapacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-highregional-unmet-need 7.4.3 IND/CTA-filed 72 7.4.4 Phase I 73 7.4.5 Phase II 74 7.4.6 Phase III 76 7.4.7 Pre-Registration 76 7.4.8 Undisclosed 77 7.5 Market Forecasts to 2019 77 7.5.1 Asia-Pacific Markets 77 7.5.2 Australia 78 7.5.3 India 79 7.5.4 China 80 7.5.5 Japan 81 7.6 Research Methodology 82 7.6.1 Coverage 82 7.6.2 Secondary Research 83 7.6.3 Primary Research 83 7.6.4 Therapeutic Landscape 83 7.6.5 Geographical Landscape 86 7.6.6 Pipeline Analysis 86
7.7 Expert Panel Validation 86 7.8 Contact Us 86 7.9 Disclaimer 86 List of Tables Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 11 Table 2: Gastrointestinal Therapeutics Market, Treatment Recommendations for Irritable Bowel Syndrome, 2009 15 Table 3: Gastrointestinal Therapeutics Market, Classification of Ulcerative Colitis, 2004 15 Table 4: Gastrointestinal Therapeutics Market, Diagnosis of Ulcerative Colitis, 2007 18 Table 5: Gastrointestinal Therapeutics Market, Difference Between Ulcerative Colitis and Crohn's Disease, 2007 18 Read Complete Report with TOC @ http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asiapacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-highregional-unmet-need Table 6: Gastrointestinal Therapeutics Market, Treatment Options of Ulcerative Colitis, 2011 21 Table 7: Gastrointestinal Therapeutics Market, Classification of Crohn's Disease, 2013 21 Table 8: Gastrointestinal Therapeutics Market, Percentage of Patients Affected by Symptoms of Crohn's Disease (%), 2012 22 Table 9: Gastrointestinal Therapeutics Market, Treatment Options for Crohn's Disease, 2009 25 Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 71 Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 71 Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 72 Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 73 Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 74 Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 76 Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 76 Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 77 Table 18: Gastrointestinal Therapeutics Asia-Pacific Markets, Irritable Bowel Syndrome, Market Forecast, 2012-2019 77 Table 19: Gastrointestinal Therapeutics Market, Asia-Pacific Markets, Ulcerative Colitis, Market Forecast, 2012-2019 78
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. For more information visit: Radiant Insights Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://www.esorics2010.org/